a multifaceted factory for Ca(2+) signaling and lipid transport
All participants were 18 years or older, planned to initiate HCV antiviral treatment, and provided written informed consent to participate in a single-center, open-label study (ClinicalTrials.gov Identifier: NCT02734173), which was approved by The Ottawa Health Science Network Research Ethics Board (REB 2015-0305, Ottawa, Ontario, Canada)
Side Effects and Safety Concerns GHK-Cu safety depends on route, formulation, dose, product quality, population, and whether the use is cosmetic, clinical, compounded, or investigational [8], [11]
The most effective strategy involves implementing sustainable lifestyle changes well before stopping the medication, rather than waiting until after discontinuation